119th Congress
S. 1095
Stop STALLING Act
- Introduced
- In committee
- Passed Senate
- Passed House
- To President
- Became law
- Sponsor
- Amy Klobuchar(D-MN)
- Introduced
- Mar 24, 2025
- Policy area
- Health
- Committees
- Senate Committee on the Judiciary
- Official text
- Reported to Senate · Congress.gov page
Cosponsors (6)
Original cosponsors (6)
- Chuck Grassley (R-IA)
- Cory A. Booker (D-NJ)
- Peter Welch (D-VT)
- Richard Blumenthal (D-CT)
- Richard J. Durbin (D-IL)
- Ted Cruz (R-TX)
Summary
Summary by the Congressional Research Service· describes the “Introduced in Senate” version
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Roll-call votes
No recorded votes on this bill.
Actions
- Apr 10, 2025 · Senate
Placed on Senate Legislative Calendar under General Orders. Calendar No. 45. - Apr 10, 2025 · Senate
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report. - Apr 3, 2025 · Senate
Committee on the Judiciary. Ordered to be reported without amendment favorably. - Mar 24, 2025 · Senate
Read twice and referred to the Committee on the Judiciary. - Mar 24, 2025
Introduced in Senate